

ASX ANNOUNCEMENT

Appendix 4C Quarterly Cash Flow Report For the Quarter Ending 30 September 2019

iQ3Corp Ltd (“iQ3” or “Company”) (ASX:IQ3), a corporate finance and advisory firm specialising in the Life Science industry, releases the following commentary in relation to its Appendix 4C report for the quarter ended 30 September 2019.

The Company reports total operating cash inflows for the quarter of \$153k, and a bank balance at the end of the quarter of \$374k.

The key results are:

- The receipts from the customer for the quarter is \$1,821k compared to \$975k for previous quarter (Q4 FY19).
- The total cash inflow for Q1 FY20 was \$119k compared to a total cash outflow of \$30k total cash outflow for Q4 FY19 and \$115k for Q1 FY19.
- The cash balances at the end of the quarter was \$374k compared to \$253k at the end of Q4 FY 2019.

END

About iQ3 Corp (ASX: iQ3)

iQ3 Corp provides advice to life science companies on mergers and acquisitions, strategic matters, restructuring and capital structure, capital raising and corporate finance to corporations, partnerships, institutions, governments, and individuals. iQ3 is a core member of The iQ Group Global.

About The iQ Group Global

The iQ Group Global is a consortium of companies that find, fund and develop bioscience discoveries into life-changing medical innovations. www.theiigroupglobal.com

Contact

Registered office:	Level 9, 85 Castlereagh Street, Sydney 2000
Contact address:	Level 9, 85 Castlereagh Street, Sydney 2000
Phone:	+61 2 8239 5400
Email:	info@theiigroup.com.au
Fax:	+61 2 8362 9547
Website address:	www.iQ3Corp.com

+Rule 4.7B

Appendix 4C

Quarterly report for entities subject to Listing Rule 4.7B

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16

Name of entity

iQ3Corp Ltd	
ABN	Quarter ended ("current quarter")
63 160 238 282	30 September 2019

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (3 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	1,821	1,821
1.2 Payments for		
(a) research and development	-	-
(b) product manufacturing and operating costs	(190)	(190)
(c) advertising and marketing	(17)	(17)
(d) leased assets	-	-
(e) staff costs	(1,217)	(1,217)
(f) administration and corporate costs	(214)	(214)
1.3 Dividends received (see note 3)		
1.4 Interest received	-	-
1.5 Interest and other costs of finance paid	(30)	(30)
1.6 Income taxes paid		
1.7 Government grants and tax incentives		
1.8 Other (provide details if material)		
1.9 Net cash from / (used in) operating activities	153	153
2. Cash flows from investing activities		
2.1 Payments to acquire:		
(a) property, plant and equipment	(14)	(14)
(b) businesses (see item 10)		
(c) investments	(20)	(20)

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (3 months) \$A'000
(d) intellectual property		
(e) other non-current assets		
2.2 Proceeds from disposal of:		
(a) property, plant and equipment		
(b) businesses (see item 10)		
(c) investments		
(d) intellectual property		
(e) other non-current assets		
2.3 Cash flows from loans to other entities		
2.4 Dividends received (see note 3)		
2.5 Other (costs of establishing new teams)		
2.6 Net cash from / (used in) investing activities	(34)	(34)
3. Cash flows from financing activities		
3.1 Proceeds from issues of shares		
3.2 Proceeds from issue of convertible notes		
3.3 Proceeds from exercise of share options		
3.4 Transaction costs related to issues of shares, convertible notes or options		
3.5 Proceeds from borrowings		
3.6 Repayment of borrowings		
3.7 Transaction costs related to loans and borrowings		
3.8 Dividends paid		
3.9 Other (movements in related party accounts)		
3.10 Net cash from / (used in) financing activities	-	-
4. Net increase / (decrease) in cash and cash equivalents for the period		
4.1 Cash and cash equivalents at beginning of quarter/year to date	253	253
4.2 Net cash from / (used in) operating activities (item 1.9 above)	153	153
4.3 Net cash from / (used in) investing activities (item 2.6 above)	(34)	(34)

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (3 months) \$A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	-	-
4.5	Effect of movement in exchange rates on cash held	2	2
4.6	Cash and cash equivalents at end of quarter	374	374

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	374	253
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (trust account)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	374	253

6. Payments to directors of the entity and their associates

- 6.1 Aggregate amount of payments to these parties included in item 1.2
- 6.2 Aggregate amount of cash flow from loans to these parties included in item 2.3
- 6.3 Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2

Current quarter \$A'000
30

Directors' remuneration

7.	Payments to related entities of the entity and their associates	Current quarter \$A'000
7.1	Aggregate amount of payments to these parties included in item 1.2	119
7.2	Aggregate amount of cash flow from loans to these parties included in item 2.3	
7.3	Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2	

Consulting fees and office sharing costs

8.	Financing facilities available <i>Add notes as necessary for an understanding of the position</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
8.1	Loan facilities	-	-
8.2	Credit standby arrangements	-	-
8.3	Other (please specify)	-	-
8.4	Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.		

9.	Estimated cash outflows for next quarter	\$A'000
9.1	Research and development	-
9.2	Product manufacturing and operating costs	196
9.3	Advertising and marketing	18
9.4	Leased assets	-
9.5	Staff costs	1,253
9.6	Administration and corporate costs	221
9.7	Other (provide details if material)	-
9.8	Total estimated cash outflows	1,687

10.	Acquisitions and disposals of business entities (items 2.1(b) and 2.2(b) above)	Acquisitions	Disposals
10.1	Name of entity		
10.2	Place of incorporation or registration		
10.3	Consideration for acquisition or disposal		
10.4	Total net assets		
10.5	Nature of business		

